Abstract
Crohn’s disease (CD) is an immune-mediated gastrointestinal inflammatory disease, which could arise from an interplay between genetic and environmental factors. Klebsiella microbes were suggested to have a vital role in the initiation and perpetuation of the disease through the mechanism of molecular mimicry. This proposition is based on the results of various studies where significantly elevated levels of antibodies against the whole bacteria or preparations from Klebsiella microbes and antibodies to collagen types I, III, IV, and V were detected in patients with CD and patients with ankylosing spondylitis (AS). Molecular similarities were found between Klebsiella nitrogenase and HLA-B27 genetic markers and between Klebsiella pullulanase and collagen fibers types I, III, and IV. Furthermore, significantly positive correlations and cross-reactivity binding activities were observed between anti-Klebsiella and anticollagen antibodies among patients with CD and AS. Early treatment of CD patients with anti-Klebsiella measures is proposed, which may involve the use of antibiotics and low starch diet together with other traditionally used immunomodulatory, immunosuppressive, or biologic agents.
Similar content being viewed by others
References
Reveille JD, Arnett FC (2005) Spondyloarthritis: update on pathogenesis and management. Am J Med 118:592–603
Stenson WF (2004) Inflammatory bowel disease. In: Goldman L, Ansiello D (eds) Cecil textbook of medicine. Saunders, Philadelphia, PA, pp 861–868
Jewell DP (2003) Crohn’s disease. In: Warrell DA, Cox TM, Firth JD, Benz EJ Jr (eds) Oxford textbook of medicine. Oxford University Press, Oxford, pp 604–611
Ebinger M, Leidl R, Thomas S, Von Tirpitz C, Reinshagen M, Adler G et al (2004) Cost of outpatient care in patients with inflammatory bowel disease in a German university hospital. J Gastroenterol Hepatol 19:192–199
Soncini M, Triossi O, Leo P, Magni G (2004) Inflammatory bowel disease and hospital treatment in Italy: the RING multi-centre study. Aliment Pharmacol Ther 19:63–68
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Meijers KA, Tytgat GN (1978) Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA-B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease. Ann Rheum Dis 37:36–41
Purrmann J, Zeidler H, Bertrams J, Juli E, Cleveland S, Berges W et al (1988) HLA antigens in ankylosing spondylitis associated with Crohn’s disease. Increased frequency of the HLA phenotype B27, B44. J Rheumatol 15:1658–1661
Huaux JP, Fiasse R, De Bruyere M, Nagant de Deuxchaisnes C (1977) HLA-B27 in regional enteritis with and without ankylosing spondylitis or sacroiliitis. J Rheumatol 3:60–63
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67
Arseneau KO, Pizarro TT, Cominelli F (2000) Discovering the cause of inflammatory bowel disease: lessons from animal model. Curr Opin Gastroenterol 16:310–317
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603
Newman B, Siminovitch KA (2005) Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol 21:401–407
Laukens D, Peeters H, Marichal D, Vander Crussen B, Mielants H, Elewaut D et al (2005) CARD 15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis 64:930–935
Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G (2003) Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124:1767–1773
Franchimont D, Belaiche J, Louis E, Simon S, GrandBastien B, Gower-Rousseau C et al (1997) Familial Crohn’s disease: a study of 18 families. Acta Gastroenterol Belg 60:134–137
Eastmond CJ, Woodrow JC (1977) Discordance for ankylosing spondylitis in monozygotic twins. Ann Rheum Dis 36:360–364
Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL et al (1997) Susceptibility of ankylosing spondylitis in twins: the role of genes, HLA and the environment. Arthritis Rheum 40:1823–1828
Van der Paardt M, Dijkmans B, Giltay E, Van der Horst-Bruinsma I (2002) Dutch patients with familial and sporadic ankylosing spondylitis do not differ in disease phenotype. J Rheumatol 29:2583–2584
Andersson RE, Olaison G, Tysk C, Ekbom A (2003) Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 124:40–46
Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364
Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E et al (1996) Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 98:945–953
Wright V (1978) Seronegative polyarthritis: a unified concept. Arthritis Rheum 21:619–633
Mielants H, Veys EM, Joos R, Cuvelier C, De Vos M (1987) Repeat ileocolonoscopy in reactive arthritis. J Rheumatol 14:456–458
Palm O, Moum B, Ongre A, Gran JT (2002) Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 29:511–515
Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D et al (2003) Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology. 125:1598–1605
Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J et al (2003) Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 30:518–522
Podswiadek M, Punzi L, Stramare R, D’Inca R, Ferronato A, Lo Nigro A et al (2004) The prevalence of radiographic sacroiliitis is patients affected by inflammatory bowel disease with inflammatory low back pain. Reumatismo 56:110–113
Ebringer R, Cooke D, Cawdell DR, Cowling P, Ebringer A (1977) Ankylosing spondylitis: Klebsiella and HLA-B27. Rheumatol Rehabil 16:190–196
Kujath K, Kekow M, Drynda S, Podschun R, Sahly H, Kekow J (2001) The presence of Klebsiella in feces and smears in patients with and without ankylosing spondylitis-isolation of multiple Klebsiella species and K serotypes (abstract). Arthritis Rheum 44 (Suppl 9):S1103
Stebbings S, Munro K, Simon MA, Tannock G, Highton J, Harmsen H et al (2002) Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatol (Oxf) 41:1395–1401
Stone MA, Payne U, Schentag C, Rahman P, Pacheco-Tena C, Inman RD (2004) Comparative immune responses to candidate arthritogenic bacteria do not confirm a dominant role for Klebsiella pneumonia in the pathogenesis of familial ankylosing spondylitis. Rheumatol (Oxf) 43:148–155
Ebringer A, Rashid T, Wilson C, Ptaszynska T, Fielder M (2006) Ankylosing spondylitis as an auto-immune disease linked to intestinal Klebsiella infection: prospects for a new therapeutic approach. Curr Rheumatol Rev 2:55–68
Blankenberg-Sprenkels SHD, Fielder M, Feltkamp TEW, Tiwana H, Wilson C, Ebringer A (1998) Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol 25:743–747
Maki-Ikola O, Hallgren R, Kanerud L, Feltelius N, Knutsson L, Granfors K (1997) Enhanced jejunal production of antibodies to Klebsiella and other Enterobacteria in patients with ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 56:421–425
Schwimmbeck PL, Yu DTY, Oldstone MBA (1987) Autoantibodies to HLA-B27 in the sera of HLA-B27 patients with ankylosing spondylitis and Reiter’s syndrome: molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 166:173–181
Charalambous BM, Keen JN, McPherson MJ (1988) Collagen-like sequences stabilize homotrimers of a bacterial hydrolase. EMBO J 7:2903–2909
Husby G, Tsuchiya N, Schwimmbeck PL, Keat A, Pahle JA, Oldstone MB et al (1989) Cross-reactive epitope with Klebsiella pneumoniae nitrogenase in articular tissue of HLA-B27+ patients with ankylosing spondylitis. Arthritis Rheum 32:437–445
Wilson C, Rashid T, Tiwana H, Beyan H, Hughes L, Bansal S et al (2003) Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 30:972–978
Plessier A, Cosnes J, Gendre JP, Beaugerie L (2002) Intercurrent Klebsiella oxytoca colitis in a patient with Crohn’s disease. Gastroenterol Clin Biol 26:799–800
Horing E, Gopfert D, Schroter G, von Gaisberg U (1991) Frequency and spectrum of microorganisms isolated from biopsy specimens in chronic colitis. Endoscopy 23:325–327
Walmsley RS, Anthony A, Sim R, Pounder RE, Wakefiled AJ (1998) Absence of Escherichia coli, Listeria monocytogenes and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol 51:657–661
Ibbotson JP, Pease PE, Allan RN (1987) Serological studies in Crohn’s disease. Eur J Clin Microbiol 6:286–290
Cooper R, Fraser SM, Sturrock RD, Gemmell CG (1988) Raised titres of anti-Klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Br Med J 296:1432–1434
O’Mahony S, Anderson N, Nuki G, Ferguson A (1992) Systemic and mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn’s disease. Ann Rheum Dis 51:1296–1300
Tiwana H, Wilson C, Walmsley RS, Wakefiled AJ, Smith MS, Cox NL et al (1997) Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Rheumatol Int 17:11–16
Tiwana H, Walmsley RS, Wilson C, Yiannakou JY, Ciclitira PJ, Wakefield AJ et al (1998) Characterization of the humoral immune response to Klebsiella species in inflammatory bowel disease and ankylosing spondylitis. Br J Rheumatol 37:525–531
Tiwana H, Natt RS, Benitez–Brito R, Shah S, Wilson C, Bridger S et al (2001) Correlation between the immune responses to collagens type I, III, IV and V and Klebsiella pneumoniae in patients with Crohn’s disease and ankylosing spondylitis. Rheumatol (Oxf) 40:15–23
Demetter P, De Vos M, Van Huysse JA, Baeten D, Ferdinande L, Peeters H et al (2005) Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 64:321–324
Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M et al (2002) Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 196:343–350
De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H et al (1998) Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 24:785–813
De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys EM (1996) Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 110:1696–1703
Siegert S, Yin Z, Radburch A, Sieper J, Braun J (1998) Evidence for a different cytokine secretion pattern of peripheral blood mononuclear cells (PBC) of HLA B27+ patients with ankylosing spondylitis (AS) and HLA B27+ healthy controls compared to HLA B27-negative controls. Arthritis Rheum 41(Suppl 9):1530
Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G et al (2001) Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 60:495–499
Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C et al (1995) Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett 369:243–248
Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S et al (1988) Collagen content and types in the intestinal strictures of Crohn’s disease. Gastroenterology 94:257–265
Stallmach A, Schuppan D, Riese HH, Matthes H, Riecken EO (1992) Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn’s disease. Gastroenterology 102:1920–1929
Anderson IH, Levine AS, Levitt MD (1981) Incomplete absorption of the carbohydrate in all-purpose wheat flour. N Engl J Med 304:891–892
Sandborn WJ (2003) Evidence-based treatment algorithm for mild to moderate Crohn’s disease. Am J Gastroenterol 98 (Suppl 12):S1–S5
Siegel CA, Sands BE (2005) Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 22:1–16
Travassos WJ, Cheifetz AS (2005) Infliximab: use in inflammatory bowel disease. Curr Treat Options Gastroenterol 8:187–196
Hanauer SB, Sanborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333
Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke J et al (2006) Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn’s disease. Am J Gastroenterol 101:793–797
Tobon GJ, Canas C, Jaller J, Restrepo J, Anaya J (2006) Serious liver disease induced by infliximab. Clin Rheumatol (in press). DOI 10.1007/s10067-005-0169-y
Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J et al (1982) A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology 83:550–562
Greenbloom SL, Steinhart AH, Greenberg GR (1998) Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol 12:53–56
Leiper K, Morris AI, Rhodes JM (2000) Open label trial of oral clarithromycin in active Crohn’s disease. Aliment Pharmacol Ther 14:801–806
Arnold GL, Beaves MR, Pryjdun VO, Mook WJ (2002) Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis 8:10–15
Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J et al (2002) Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn’s disease. J Immunol 169:5308–5314
Wild GE (2004) The role of antibiotics in the management of Crohn’s disease. Inflamm Bowel Dis 10:321–323
Thukral C, Travassos WJ, Peppercorn MA (2005) The role of antibiotics in inflammatory bowel disease. Curr Treat Options Gastroenterol 8:223–228
Aberra FN, Brensinger CM, bilker WB, Lichtenstein GR, Lewis JD (2005) Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol 3:459–465
Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M (2005) Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 51(Suppl 1):96–102
Hemphill A, Mueller J, Esposito M (2006) Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin Pharmacother 7:953–964
Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G et al (1991) Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 32:1071–1075
Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K et al (2002) Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomised controlled trial. Gastroenterology 123:33–40
Rioux KP, Fedorak RN (2006) Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 40:260–263
Kleessen B, Stoof G, Proll J, Schmiedl D, Noack J, Blaut M (1997) Feeding resistant starch affects fecal and cecal microflora and short-chain fatty acids in rats. J Anim Sci 75:2453–2462
Ebringer A, Baines M, Childerstone M, Ghuloom M, Ptaszynska T (1985) Etiopathogenesis of ankylosing spondylitis and the cross-tolerance hypothesis. In: Ziff M, Cohen SB (eds) Advances in inflammation research—the spondyloarthropathies. Raven, New York, pp 101–128
Finegold SM, Sutter VL, Sugihara PT, Elder HA, Lehmann SM, Phillips RL (1977) Fecal microbial flora in Seventh Day Adventist populations and control subjects. Am J Clin Nutr 30:1781–1792
Ebringer A, Wilson C (1996) The use of low starch diet in the treatment of patients suffering from ankylosing spondylitis. Clin Rheumatol 15(Suppl 1):62–66
Acknowledgements
We thank the Trustees of the Middlesex Hospital, the Arthritis Research Campaign (Grant EO514), and “American Friends of King’s College London” for their support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ebringer, A., Rashid, T., Tiwana, H. et al. A possible link between Crohn’s disease and ankylosing spondylitis via Klebsiella infections. Clin Rheumatol 26, 289–297 (2007). https://doi.org/10.1007/s10067-006-0391-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0391-2